Trial · NCT02652806
FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease
NCT02652806, Phase 3, Completed, Kyntra Bio
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease. Trials, record NCT02652806. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02652806
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease
- NCT number
- NCT02652806
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 305 participants, actual
- Lead sponsor
- Kyntra Bio
- Conditions
- Anemia
- Interventions
- FG-4592, Epoetin Alfa
- First posted
- 2016-01-12
- Last updated
- 2017-08-24
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hb mean change from baseline | Weeks 23 to 27. | Hb mean change from baseline |
| Secondary | Mean change from baseline in low-density lipoprotein (LDL) cholesterol | Weeks 25-27 | Mean change from baseline in low-density lipoprotein (LDL) cholesterol |
| Secondary | Number of subjects with a Hb response | Weeks 23-27 | Number of subjects with a Hb response (as defined per protocol) |
| Secondary | Percent of subjects with a Hb response | Weeks 23-27 | Percent of subjects with a Hb response (as defined per protocol) |
| Secondary | Effect on iron metabolism | Week 27 | Measurement of serum iron |
| Secondary | Proportion of subjects with exacerbation of hypertension | Up to Week 27 | Proportion of subjects with exacerbation of hypertension, meeting at least one of the following criteria up to Week 27: * Increase in anti-hypertensive medication use, * Adverse event of hypertension, or * Increases from baseline in blood pressure confirmed by repeat measurement at next visit unless anti-hypertensive medications are changed. |
| Secondary | Mean change from baseline in predialysis and postdialysis mean arterial blood pressure | Weeks 23-27 | Mean arterial blood pressure measured pre-and post-dialysis. |
| Secondary | Number of subjects with treatment-emergent adverse events (TEAEs). | Week 1 to up to Week 53 | Number of subjects with treatment-emergent adverse events (TEAEs). |
| Secondary | Percent of subjects with treatment-emergent adverse events (TEAEs). | Week 1 to up to Week 53 | Percent of subjects with treatment-emergent adverse events (TEAEs). |
| Secondary | Changes from baseline in vital signs | Week 1 to up to Week 53 | Measurement of vital signs |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02652806
GET https://conductscience.org/api/trials/v1/NCT02652806/registered